New experimental evidence supports the idea that future therapeutic strategies for treating cardiovascular disease could target sites within the brain. Our recent study demonstrates the existence of ...
Panelists discuss how β-blockers remain foundational therapy for heart failure with reduced ejection fraction (using evidence-based agents like carvedilol, metoprolol succinate, or bisoprolol) with ...
First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with ...
Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms, left ...
Imagine someone you care about suddenly experiencing chest pain, turning pale, and breathing heavily. These are some of the symptoms of a heart attack. Cardiovascular diseases (CVDs) are the leading ...
A major new analysis from the REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro ...
Among stable, relatively low-risk patients who had previously suffered a heart attack, discontinuing beta-blockers after at least one year was found to be non-inferior, or comparable, to continuing ...
Losartan may help stop the epileptic process in certain patients with hypertension. An observational study that analyzed medical records of 2.26 million patients with hypertension found a roughly 30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results